The short answer
GLP-1 alone was not enough, and two answers emerged for what to add. Tirzepatide adds GIP receptor agonism within one molecule; CagriSema adds an amylin analogue as a second molecule. REDEFINE 4 tested those strategies against each other for the first time.
Key facts
- Tirzepatide's second target
- GIP receptor
- CagriSema's second target
- Amylin receptor
- Tirzepatide format
- One molecule
- CagriSema format
- Two molecules combined
- First direct test
- REDEFINE 4 (NCT06131437)
- Retatrutide's answer
- Glucagon, as a third receptor
Why a second target was needed
GLP-1 receptor agonism alone reached a ceiling. Semaglutide's 13.7% in SURMOUNT-5 was a real achievement and clearly not the end of what was possible. Every subsequent programme is an answer to the same question, what to add, and the answers diverged sharply.
The GIP answer
Add the other incretin. GIP and GLP-1 are the two hormones behind the incretin effect, and their receptors are structurally related enough that one engineered peptide can engage both. Tirzepatide does this within a single molecule, which is why it has one pharmacokinetic profile rather than two. The mechanism by which GIP contributes remains disputed.
Research material referenced
Retatrutide 10mg, third-party HPLC tested
The amylin answer
Add a different satiety pathway entirely. Amylin is co-secreted with insulin and signals satiety through routes distinct from the incretins, including hindbrain structures. Cagrilintide is a long-acting amylin analogue, and CagriSema pairs it with semaglutide as two molecules in one injection, a different pharmacology and a different format at once.
Why REDEFINE 4 could not cleanly separate them
Because the two things vary together. CagriSema differs from tirzepatide in both its second target and its format (amylin versus GIP, and two molecules versus one). A single trial comparing them cannot attribute the difference to either, which is a real limitation of what that comparison could ever establish.
What it did establish
That on this comparison, at these doses, over 84 weeks, CagriSema did not demonstrate non-inferiority to tirzepatide 15 mg: 23.0% against 25.5% on the efficacy estimand. That is one comparison at one dose pair, not a verdict on amylin as a target, and amylin agonists continue in development including within single molecules such as amycretin.
And the third answer
Retatrutide adds glucagon receptor agonism as a third target rather than a second, staying within one molecule. Its direct comparison with tirzepatide, TRIUMPH-5, was scheduled to reach primary completion in November 2026. All three of these are licensed medicines or investigational compounds in registered trials, and none is related to research material.
Quick reference
| Targets | Molecules | Status | |
|---|---|---|---|
| Semaglutide | GLP-1 | One | Approved |
| Tirzepatide | GLP-1 + GIP | One | Approved |
| CagriSema | GLP-1 + amylin | Two | Filed |
| Retatrutide | GLP-1 + GIP + glucagon | One | Investigational |
Frequently asked questions
Did REDEFINE 4 show GIP beats amylin?
No. CagriSema differs from tirzepatide in both target and format, so one trial cannot attribute the difference to either.
Is amylin finished as a target?
No. Development continues, including single-molecule GLP-1/amylin agonists such as amycretin.
Continue researching
Related guides and reference material.
Primary sources & clinical trials
Published papers, trial registrations, regulator pages and company announcements. Links open the original.
- TrialClinicalTrials.gov · CagriSema compared to tirzepatide (NCT06131437)clinicaltrials.gov
- PubMedDahl K et al., Amycretin, unimolecular GLP-1 and amylin receptor agonist. Lancet 2025 (PMID 40550231)pubmed.ncbi.nlm.nih.gov
- PubMedThe Paradox and Future of GLP-1/GIP Combination Therapies. Annu Rev Nutr 2026 (PMID 42166683)pubmed.ncbi.nlm.nih.gov
- RefSURMOUNT-5: Tirzepatide as compared with semaglutide. NEJMnejm.org
Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).
Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.
More GLP-1 & Incretin Science articles
- Semaglutide and Liver Disease: What ESSENCE TestedA 1,205-participant Phase 3 in metabolic dysfunction-associated steatohepatitis, published in NEJM in June 2025. What it measured and why liver trials are hard.
- FLOW: A Kidney Outcome Trial, Stopped Early3,533 participants with type 2 diabetes and chronic kidney disease. What FLOW measured, and why it is a harder kind of evidence than a weight trial.
- SELECT: The Trial That Changed What the Class Was For17,604 participants with obesity and cardiovascular disease but no diabetes. Why studying that population specifically was the point.
- The Attribution Problem Running Through Every IndicationHeart, kidney and liver benefits all appear alongside substantial weight reduction. Separating the two is harder than it looks, and mostly has not been done.
- Why Biopsy Endpoints Make Liver Trials HardMASH trials score liver biopsies for inflammation and fibrosis. A pathologist's judgement is a noisier endpoint than a number from a machine.